Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jan 12, 2018
Adapsyn signed a USD 162 million deal with Pfizer for microbe-mining project Adapsyn has recently signed a deal with Pfizer for the microbe-mining with the help of advance platform developed by the Canadian company adapsyn. The technique offers a quick filter for promising candidates with better efficacy. Due to the...
Read More...
Jan 05, 2018
Centrexion Therapeutics has raised a total of USD 67 million to fund phase 3 pain trial Jeffrey Kindler‘s managed biotech company Centrexion Therapeutics has raised $67 million. The funds will be used to promote nonopioid pain drug candidate CNTX-4975 into a phase 3 trial with patients suffering from knee osteoarth...
Read More...
Dec 19, 2017
Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...
Read More...
Nov 28, 2017
Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...
Read More...
Feb 21, 2017
USFDA warns Bengaluru-based Resonance Labs of manufacturing norms violations US health regulator USFDA has red-flagged significant deviations from manufacturing norms at the Bengaluru-based API facility of Resonance Laboratories, including failure to have adequate cleaning procedures to prevent contamination of prod...
Read More...
Jan 31, 2017
AstraZeneca announces availability of Saxa / Dapa FDC in UK UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dose combination of saxagliptin and dapagliflozin. The tablet received marketing authorization from the European Commission...
Read More...
Jan 05, 2017
Greek prosecutors raid Novartis offices, disclose wide-ranging probe into bribery allegations Greek officials announced that they are investigating Novartis for bribery in the wake of local media reports raising questions about the company. It is the fourth set of bribery allegations against the Swiss drugmaker to g...
Read More...
Nov 23, 2016
Novartis Buys Blood Disease Drug Maker for $665mn Novartis has acquired Selexys Pharmaceuticals, a drug maker specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II tr...
Read More...
Oct 18, 2016
Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community Merck has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, conc...
Read More...
Sep 15, 2016
Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to the results of Phase III data, and has also shown great stats that could prove that it might have an edge in the hotly co...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper